Skip to main content
SpringerLink
Log in

Psychopharmacotherapy

  • Chapter
Anxiety Disorders

Part of the book series: Current Clinical Practice ((CCP))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nemeroff CB. Anxiolytics: past, present, and future agents. J Clin Psychiatry 2003;64 (suppl 3):3–6.

    CAS  PubMed  Google Scholar 

  2. Stein MB. Anxiety disorders: somatic treatment. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 8th ed., vol. 1. Philadelphia: Lippincott Williams and Wilkins, 2003:1780–1787.

    Google Scholar 

  3. Hudziak J, Waterman GS. Buspirone. In: Sadock BJ, Sadock VA eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 8th ed., vol. 2. Philadelphia: Lippincott Williams and Wilkins, 2003:2797–2801.

    Google Scholar 

  4. Davidson JRT, Connor KM. Treatment of anxiety disorders. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:913–934.

    Google Scholar 

  5. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 2006;67(suppl 4):14–21.

    CAS  PubMed  Google Scholar 

  6. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 2006;67(suppl 4):3–7.

    CAS  PubMed  Google Scholar 

  7. Hollifield M, Mackey A, Davidson J. Integrated therapies for anxiety disorders. Psychiatr Ann 2006;36(5):329–338.

    Google Scholar 

  8. Nemeroff CB, Putnam JS. Antihistamines. In: Sadock BJ, Sadock VA eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 8th ed., vol. 2. Philadelphia: Lippincott Williams and Wilkins, 2003: 2772–2775.

    Google Scholar 

  9. Sussman N. General Principles of Psychopharmacology. In: Sadock BJ, Sadock VA eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 8th ed., vol. 2. Philadelphia: Lippincott Williams and Wilkins, 2003:2676–2699.

    Google Scholar 

  10. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001;62 (suppl):5–9.

    PubMed  Google Scholar 

  11. National Institute of Mental Health. Anxiety disorders. http://www.nimh.nih.gov/publicat/anxiety.cfm.

  12. Waldron T, et al. Pharmacological approaches to treating anxiety disorders: new research. Psychiatric Times's Insight Into Anxiety 2004;Jan(suppl):1–8.

    Google Scholar 

  13. Rosenbaum JF, Tollefson GD. Fluoxetine. In: Schatzberg A F, Nemeroff CB eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:231–246.

    Google Scholar 

  14. Shim J, Yonkers KA. Sertraline. In: Shatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:247–257.

    Google Scholar 

  15. Herr KD, Nemeroff CB. Paroxetine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:259–281.

    Google Scholar 

  16. Fairbanks JM, Gorman JM. Fluvoxamine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:283–290.

    Google Scholar 

  17. Roseboom PH, Kalin NH. Citalopram and s-citalopram. In: Shatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:291–302.

    Google Scholar 

  18. Kelsey JE. Selective Serotonin Reuptake Inhibitors. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 8th ed., vol. 2. Philadelphia: Lippincott Williams and Wilkins, 2005:2887–2913.

    Google Scholar 

  19. Davidson J. Managing anxiety disorders: psychopharmacologic treatment options. Psychiatric Times April 2006;80–83.

    Google Scholar 

  20. PDR Precise Prescribing Guide. Psychiatry. Issue 3. Montvale, NJ: Thompson PDR, 2006.

    Google Scholar 

  21. Marangell LB, Silver JM, Goff DC, Yudofsky SC. Psychopharmacology and electroconvulsive therapy. In: The American Psychiatric Publishing Textbook of Clinical Psychiatry, 4th ed., Washington, DC: American Psychiatric Publishing, 2003:1047#x2013;1083.

    Google Scholar 

  22. Alva G, Siegal AP, et al. Challenges in the treatment of anxiety and depression in the elderly patient. CNS News 2006;July:41#x2013;48.

    Google Scholar 

  23. Physicians Desk Reference, 60th ed. Montvale, NJ: Thompson PDR, 2006.

    Google Scholar 

  24. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13#x2013;37.

    Article  CAS  PubMed  Google Scholar 

  25. DeBattista C, Schatzberg AF. 2003 psychotropic dosing and monitoring guidelines. Prim Psychiatry 2003;July:80#x2013;96.

    Google Scholar 

  26. DeVane CL. Living with an ambiguity in clinical practice: antidepres-sant drug-drug interactions. Insights into Depression and Anxiety, Supplement to Psychiatric Times 2006;Feb:1–8.

    Google Scholar 

  27. Mrazek DA, Smoller, de Leon J. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Roundtable monograph supplement. CNS Spect 2006;11(3, suppl 3):1#x2013;13.

    Google Scholar 

  28. Venkatakrishnan K, Shader RI, von Moltke LL, Greenblatt DJ. Drug interactions in psychopharmacology. In: Shader RI, ed. Manual of Psychiatric Therapeutics, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003:441–469.

    Google Scholar 

  29. Hamer AM. Optimizing treatment of depression in the elderly patient. Insights into Depression and Anxiety, Supplement to Psychiatric Times 2005;Jan:1–8.

    Google Scholar 

  30. Roose SP, Pollock BC, Devanand DP. Treatment during late-life. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:1083–1091.

    Google Scholar 

  31. Cytochrome P450 drug-interaction table. http://medicine.iupui.edu/flockhart/.

  32. Shelton RC, Lester N. Selective serotonin reuptake inhibitors and newer antidepressants. In: Stein DJ, Kupfer DJ, Schatzberg AF, eds. The American Psychiatric Publishing Textbook of Mood Disorders, 1st ed. Arlington, VA: American Psychiatric Publishing, 2006:263–280.

    Google Scholar 

  33. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(suppl 6):33–37.

    PubMed  Google Scholar 

  34. Newport DJ, Fisher A, Graybeal S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:1109–1136.

    Google Scholar 

  35. Pies R. Prenatal antidepressant use: time for a pregnant pause. Psychiatric Times http://www.psychiatrictimes.com/article/showArticle/ jhtml?articleId=193006232.

    Google Scholar 

  36. King EZ, Stowe ZN, Newport DJ. Using antidepressants during pregnancy: an update. Psychiatric Times http://psychiatrictimes.com/article/ showArticle.jhtml?articleId=102202123.

    Google Scholar 

  37. FDA Public Health Advisory. Treatment challenges of depression in pregnancy. http://www.fda.gov/cder/drug/advisory/SSRI_PPHN200607.htm.

    Google Scholar 

  38. Rubinchik SM, Kablinger AS, Gargner JS. Medications for panic disorder and generalized anxiety disorder during pregnancy. Prim Care Companion J Clin Psychiatry 2005;7(3):100–105.

    Article  PubMed  Google Scholar 

  39. Psychiatric News. What is the evidence base for using SSRIs during pregnancy? 2006(April 21);41;8:14. http://pn.psycjiatryonline.org/cgi/ content/full/41/8/14—a.

    Google Scholar 

  40. Hasser C, Brizendine L, Spielvogel A. SSRI use during pregnancy. Current Psychiatry 2006;5:31–40.

    Google Scholar 

  41. MedPage Today. Avoid Paxil in pregnancy, ACOG committee advises. http://www.medpagetoday.com/tbprint.cfm?tbid=4611.

    Google Scholar 

  42. Robinson DS. Psychotropic drugs and pregnancy: guidance for antide-pressants. Prim Psychiatry 2005;12(6):22–23. http://www.primarypsychiatry. com/aspx/article_pf.aspx?articleid=92.

    Google Scholar 

  43. Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006;57;5:673–680.

    Article  PubMed  Google Scholar 

  44. Thase ME, Sloan DME. Venlafaxine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:349–360.

    Google Scholar 

  45. Delgado PL. How antidepressants help depression: mechanisms of action and clinical response. J Clin Psychiatry 2004;65(suppl 4):25–30.

    CAS  PubMed  Google Scholar 

  46. Greden JF. Duloxetine and milnacipran. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:361–370.

    Google Scholar 

  47. Raj A, Sheehan D. Benzodiazepines. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:371–380.

    Google Scholar 

  48. Rosenbaum JF, chair. Utilizing benzodiazepines in clinical practice: an evidence based discussion [academic highlights]. J Clin Psychiatry 2004;65:1565–1574.

    Article  Google Scholar 

  49. Feldman MD. Managing psychiatric disorders in primary care: 2. Anxiety. Hosp Pract 2000;35(7):77–84.

    CAS  Google Scholar 

  50. Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry 2003;64(suppl 3):21–27.

    CAS  PubMed  Google Scholar 

  51. Gorman JM. New molecular targets for antianxiety interventions. J Clin Psychiatry 2003;64(suppl 3):28–35.

    CAS  PubMed  Google Scholar 

  52. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005;66(suppl 2);9–13.

    CAS  PubMed  Google Scholar 

  53. Tinsley JA. Drug abuse. In: Rakel RE, Bope ET, eds. Conn's Current Therapy, 58th ed. Philadelphia: Saunders, 2006:1344–1345.

    Google Scholar 

  54. Rosenbaum JF. Attitudes towards benzodiazepines over the years. J Clin Psychiatry 2005;66(suppl 2):4–8.

    PubMed  Google Scholar 

  55. Ninan PT, Muntasser S. Buspirone and gepirone. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:391–404.

    Google Scholar 

  56. Feighner JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry 1999;60(suppl 22):18–22.

    CAS  PubMed  Google Scholar 

  57. Nelson JC. Tricyclic and tetracyclic drugs. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:207–230.

    Google Scholar 

  58. Krishnan KRR. Monoamine oxidase inhibitors. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Arlington, VA: American Psychiatric Publishing, 2004:303–314.

    Google Scholar 

  59. Patkar AA, Pae C-U, Masand PS. Transdermal selegiline: a new generation of monoamine oxidase inhibitors. CNS Spectr 2006;11:363–375.

    PubMed  Google Scholar 

  60. Hauser L, Anupindi R, Moore W. Hydroxyzine for the treatment of acute opioid withdrawal: a 20-year clinical experience. Resident and Staff Physician 2006;52:24–30.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Director of Mental Health/Health Education, West Virginia University Student Health Service, Morgantown, West Virginia, USA

    John R. Vanin (Professor of Behavioral Medicine and Psychiatry/Family Medicine)

Authors
  1. John R. Vanin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

Vanin, J.R. (2008). Psychopharmacotherapy. In: Anxiety Disorders. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-263-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-263-2_4

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-923-9

  • Online ISBN: 978-1-59745-263-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation